<DOC>
	<DOCNO>NCT00507130</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability escalate multiple SC dose MEDI-528 adult patient mild persistent asthma .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Administration MEDI-528 When Administered Multiple Doses Adults With Mild Persistent Asthma</brief_title>
	<detailed_description>The secondary objective study : 1 . Assess PK MEDI-528 ; 2 . Assess IM MEDI-528 patient population .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female adult , age 18 65 year age time screen ; Weight ≤ 100 kg body mass index ≤ 35 ; Written inform consent obtain patient prior receipt study medication begin study procedure ; Previously document diagnosis asthma base episodic symptom airflow obstruction wheeze chest tightness , alternative diagnosis ( e.g. , chronic obstructive pulmonary disease ) rule ; Currently receive treatment shortacting β2 agonist , ICS dose ≤ 264 μg/day fluticasone equivalent , ( National Heart , Lung , Blood Institute [ NHLBI ] , 2002 ) ; FEV1 peak expiratory flow ( PEF ) ≥ 80 % predictable value ; Have diagnosis mild persistent asthma , define asthma symptom frequency twice week less daily , nighttime symptoms frequency twice month less week ( NHLBI , 2002 ) ; Have AHR base documented clinical history either methacholine inhalation challenge PC20 ≤ 16 mg/mL partial reversibility ≤ 12 % FEV1 within past 18 month ( include screen ) ; Able provide spirometry reading meet American Thoracic Society/European Respiratory Society standard ( Miller , 2005 ) ; Sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral , implanted , transdermal contraceptive , intrauterine device , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 21 day prior first dose study drug , must agree continue use precaution Study Day 150 . Cessation birth control point discuss responsible physician . Sexually active male , unless surgically sterile , must likewise use effective method birth control ( condom ) must agree continue use precaution Study Day 150 ; Ability complete study period , include followup period , 150 day ; Willing forego form experimental treatment study procedure study . Receipt MEDI528 previous clinical study prior randomization trial ; History allergy reaction component MEDI528 formulation ; Lung disease persistent asthma ( e.g . chronic bronchitis ) ; FEV1 &lt; 80 % predicted value ; History severe asthma asthma exacerbation require intubation ; Use systemic immunosuppressive drug include systemic corticosteroid ICS dose &gt; 264 μg/day fluticasone equivalent within 4 week prior Study Day 0 ; Use longacting β2 agonist , theophylline , cromolyn sodium , nedocromil sodium , leukotriene receptor antagonist , inhaled systemic medication asthma ( except shortacting β2 agonist ICS dose ≤ 264 μg/day fluticasone equivalent ) within 2 week prior Study Day 0 ; Current use βadrenergic antagonist ( e.g. , propranolol ) ; Any disease illness , asthma , may require use systemic corticosteroid study period ; Acute illnesses evidence significant active infection , fever ≥ 38.0°C ( 100.5°F ) screening time first dose study drug ; Current allergy vaccination therapy ( desensitization immunotherapy ) , less 3 month stable maintenance dos prior screen ; Receipt investigational drug therapy within 30 day biologic ( ) within 5 halflives agent prior first dose study drug Study Day 150 ; Receipt therapy leukocytedepleting agent unless recovery white cell count document screening ; Pregnancy ( sexually active female must negative serum pregnancy test screen negative urine pregnancy test prior study drug administration Study Day 0 ) ; Lactating breastfeed woman ; Evidence infection hepatitis B C virus , human immunodeficiency virus1 2 ( HIV1 HIV2 ) , active infection hepatitis A ; History significant systemic disease ( e.g. , cancer , infection , hematological , renal , hepatic , coronary artery disease cardiovascular disease , endocrinologic , neurologic , rheumatologic , gastrointestinal disease ) ; History cancer nonmelanoma skin cancer cervical carcinomainsitu treat apparent success curative therapy ( remission ≥ 1 year prior screen ) ; History primary immunodeficiency ; History pancreatitis ; History use tobacco product one cigarette per month equivalent within 1 year prior randomization history smoke ≥ 10 packyears ; Elective surgery plan study period Study Day 150 ; Clinically significant abnormality physical examination ( asthma ) prior first dose study drug ( include limit splenomegaly ) ; Clinically significant abnormality , determine investigator , 12lead ECG , MRI , chest radiograph time screening ; At time screening , abnormality follow measurement : hemoglobin , total white blood cell count ( WBC ) , platelet count , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , amylase , serum creatinine upper limit normal ( ULN ) ; abnormal laboratory value screen panel , opinion principal investigator , judge clinically significant ; Evidence systemic disease respiratory disease ( asthma ) , find upon physical examination history disease , opinion investigator medical monitor , may compromise safety patient study confound analysis study ; Employees clinical study site individual involve conduct study , family member individual .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>